EUVIMEDEUVIMED entdecken
Open Access

Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions

James M Crawford iD, Lynne Penberthy, Ligia A Pinto, Keri N Althoff iD, Magdalene M Assimon, Oren Cohen, Laura Gillim, Tracy L Hammonds iD, Shilpa Kapur, Harvey W Kaufman, David Kwasny, Jean W Liew und 9 weitere

Open Forum Infectious Diseases · 23.12.2024 · 12 (1)

DOI: 10.1093/ofid/ofaf021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 23.01.2025. Verfasst von James M Crawford und 20 weiteren Autor:innen. Beteiligte Einrichtung: Northwell, Department of Pathology and Laboratory Medicine, New Hyde Park, New York, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We developed a United States–based real-world data resource to better understand the continued impact of the coronavirus disease 2019 (COVID-19) pandemic on immunocompromised patients, who are typically underrepresented in prospective studies and clinical trials.

Methods

The COVID-19 Real World Data infrastructure (CRWDi) was created by linking and harmonizing de-identified HealthVerity medical and pharmacy claims data from 1 December 2018 to 31 December 2023, with severe acute respiratory syndrome coronavirus 2 virologic and serologic laboratory data from major commercial laboratories and Northwell Health; COVID-19 vaccination data; and, for patients with cancer, 2010 to 2021 National Cancer Institute Surveillance, Epidemiology, and End Results registry data.

Results

The CRWDi contains 4 cohorts: patients with cancer; patients with rheumatic diseases receiving pharmacotherapy; noncancer solid organ and hematopoietic stem cell transplant recipients; and people from the general population including adults and pediatric patients. The project successfully linked and harmonized longitudinal, de-identified data on 5.2 million unique patients using privacy-preserving record lineage techniques. The system was developed in early 2024 and rapidly deployed, enabling longitudinal analysis of patient healthcare over the full geography of delivery settings and exploration of novel questions for populations at high risk for adverse outcomes.

Conclusions

The successful development of the CRWDi enables researchers to address unanswered questions that have arisen during the COVID-19 pandemic. By making the data broadly and freely available to academic researchers, this real-world data system represents an important complement to existing consortia and clinical trials that have emerged during the healthcare crisis and is readily reproducible for future purposing.

Schlagwörter

Stichwörter der Autor:innen

SARS-CoV-2SEERimmunocompromisedserologyvaccination

Autor:innen und Institutionen

  • Northwell, Department of Pathology and Laboratory Medicine, New Hyde Park, New York, USA.
  • Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • John Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland, USA.
  • Aetion Inc, New York, New York, USA.
  • Laboratory Corporation of America, Burlington, North Carolina, USA.

ORCID-Profile: James M Crawford, Keri N Althoff, Tracy L Hammonds, William A Meyer, Shannon L Reynolds, Yonah C Ziemba

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Crawford, J. M., Penberthy, L., Pinto, L. A., Althoff, K. N., Assimon, M. M., Cohen, O., Gillim, L., Hammonds, T. L., Kapur, S., Kaufman, H. W., Kwasny, D., Liew, J. W., Meyer, W. A., Reynolds, S. L., Schleicher, C. B., Subbiah, S., Theruviparampil, C., Wallace, Z. S., Warner, J. L., …, & Ziemba, Y. C. (2024). Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions. Open Forum Infectious Diseases, 12(1). https://doi.org/10.1093/ofid/ofaf021

Vancouver

Crawford JM, Penberthy L, Pinto LA, Althoff KN, Assimon MM, Cohen O, et al. Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions. Open Forum Infectious Diseases. 2024;12(1). doi:10.1093/ofid/ofaf021

BibTeX
@article{Crawford2024,
  author = {Crawford, James M and Penberthy, Lynne and Pinto, Ligia A and Althoff, Keri N and Assimon, Magdalene M and Cohen, Oren and Gillim, Laura and Hammonds, Tracy L and Kapur, Shilpa and Kaufman, Harvey W and Kwasny, David and Liew, Jean W and Meyer, William A and Reynolds, Shannon L and Schleicher, Cheryl B and Subbiah, Suki and Theruviparampil, Catherine and Wallace, Zachary S and Warner, Jeremy L and Yoon, Suhyeon and Ziemba, Yonah C},
  title = {Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions},
  journal = {Open Forum Infectious Diseases},
  year = {2024},
  volume = {12},
  number = {1},
  doi = {10.1093/ofid/ofaf021}
}
Kostenlos starten →